Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Metastatic HER2-Negative Inflammatory Breast Cancer
NCT02389764Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2015
- Primary completion
- Jun 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in inflammatory breast cancer (IBC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2015; status: terminated.
02
Drugs
nintedanib
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT02389764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389764.